Prevention programmes of progressive renal disease in developing nations (Review Article)
暂无分享,去创建一个
[1] Miguel Almaguer-López,et al. Strategies for national health care systems and centers in the emerging world: Central America and the Caribbean--the case of Cuba. , 2005, Kidney international. Supplement.
[2] R. Dyck. Tracking ancient pathways to a modern epidemic: diabetic end-stage renal disease in Saskatchewan aboriginal people. , 2005, Kidney international. Supplement.
[3] L. Reyes,et al. Long-term consequences of low birth weight. , 2005, Kidney international. Supplement.
[4] J. Maccluer,et al. Kidney disease among the Zuni Indians: the Zuni Kidney Project. , 2005, Kidney international. Supplement.
[5] B. Caballero. A nutrition paradox--underweight and obesity in developing countries. , 2005, The New England journal of medicine.
[6] M. Mani. Experience with a program for prevention of chronic renal failure in India. , 2005, Kidney international. Supplement.
[7] T. Nagasawa,et al. Erythropoietin‐resistant anaemia in a predialysis patient with Klinefelter syndrome , 2005, Nephrology.
[8] Z. Morad,et al. Prevention of renal failure: The Malaysian experience , 2005, Kidney International.
[9] G. Remuzzi,et al. Albuminuria as early test for vascular disease , 2005, The Lancet.
[10] Hans L. Hillege,et al. Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria , 2004, Circulation.
[11] R. Rodby,et al. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting , 2004, Journal of Human Hypertension.
[12] P. Lapuerta,et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and re , 2004, Diabetes care.
[13] N. Powe,et al. Screening for proteinuria in US adults: a cost-effectiveness analysis. , 2003, JAMA.
[14] Giuseppe Remuzzi,et al. The future of renoprotection: Frustration and promises , 2003 .
[15] A. Collins,et al. Chronic kidney disease and cardiovascular disease in the Medicare population. , 2003, Kidney international. Supplement.
[16] G. Maguire,et al. Renal function and cardiovascular risk markers in a remote Australian Aboriginal community. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[17] R. Nelson,et al. Testing for microalbuminuria in 2002: barriers to implementing current guidelines. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[18] David W Dunstan,et al. Prevalence of kidney damage in Australian adults: The AusDiab kidney study. , 2003, Journal of the American Society of Nephrology : JASN.
[19] Neil R. Powe,et al. Lifestyle Factors, Obesity and the Risk of Chronic Kidney Disease , 2003, Epidemiology.
[20] K. Iseki. The okinawa screening program. , 2003, Journal of the American Society of Nephrology : JASN.
[21] B. Brenner,et al. Dialysis delayed is death prevented: a clinical perspective on the RENAAL study. , 2003, Kidney international.
[22] W. McClellan,et al. Taking a public health approach to the prevention of end-stage renal disease: the NKF Singapore Program. , 2003, Kidney international. Supplement.
[23] S. Naicker,et al. End-stage renal disease in sub-Saharan and South Africa. , 2003, Kidney international. Supplement.
[24] M. Mani. Prevention of chronic renal failure at the community level. , 2003, Kidney international. Supplement.
[25] R. Zatz,et al. Nephrology in Latin America, with special emphasis on Brazil. , 2003, Kidney international. Supplement.
[26] Joel Lexchin,et al. The pharmaceutical industry as a medicines provider , 2002, The Lancet.
[27] Hans L Hillege,et al. Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population , 2002, Circulation.
[28] R. Barsoum. Overview: end-stage renal disease in the developing world. , 2002, Artificial organs.
[29] R. Barsoum. End-stage renal disease in the developing world. , 2002, Artificial organs.
[30] V. Kher. End-stage renal disease in developing countries. , 2002, Kidney international.
[31] M. Dichgans. CADASIL: A Monogenic Condition Causing Stroke and Subcortical Vascular Dementia , 2002, Cerebrovascular Diseases.
[32] B. Dimitrov,et al. Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial , 2002, The Lancet.
[33] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.
[34] T. Usami,et al. Regional variations in the incidence of end-stage renal failure in Japan. , 2000, JAMA.
[35] R. Mañalich,et al. Relationship between weight at birth and the number and size of renal glomeruli in humans: a histomorphometric study. , 2000, Kidney international.
[36] J. Birkmeyer,et al. The Cost-Effectiveness of Treating All Patients with Type 2 Diabetes with Angiotensin-Converting Enzyme Inhibitors , 1999, Annals of Internal Medicine.
[37] J. Mathews,et al. A new dimension to the Barker hypothesis: low birthweight and susceptibility to renal disease. , 1999, Kidney international.
[38] S. Yusuf,et al. Emerging epidemic of cardiovascular disease in developing countries. , 1999, Circulation.
[39] G. Remuzzi,et al. The first clinical and epidemiological programme on renal disease in Bolivia: a model for prevention and early diagnosis of renal diseases in the developing countries. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[40] A. Disney. Some trends in chronic renal replacement therapy in Australia and New Zealand, 1997. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[41] B. Rutkowski,et al. Treatment of end-stage renal disease in central and eastern Europe: overview of current status and future needs. , 1998, Artificial organs.
[42] J. Barendregt,et al. Global burden of disease , 1997, The Lancet.
[43] B. Kiberd,et al. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation , 1995, BMJ.
[44] C. V. Howard,et al. The effect of intrauterine growth retardation on the development of renal nephrons , 1992, British journal of obstetrics and gynaecology.
[45] D. Silverberg,et al. Routine urinalysis (dipstick) findings in mass screening of healthy adults. , 1987, Clinical chemistry.
[46] G Rose,et al. Sick individuals and sick populations. , 1985, International journal of epidemiology.
[47] G. Eknoyan,et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[48] Michael J Lysaght,et al. Maintenance dialysis population dynamics: current trends and long-term implications. , 2002, Journal of the American Society of Nephrology : JASN.
[49] G. Remuzzi,et al. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. , 2001, Kidney international.
[50] T A Louis,et al. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. , 2001, Journal of the American Society of Nephrology : JASN.
[51] A. Palmer,et al. The cost-effectiveness of different management strategies for Type I diabetes: a Swiss perspective , 2000, Diabetologia.
[52] R Doll,et al. Mortality from smoking worldwide. , 1996, British medical bulletin.
[53] Lei‐shi Li,et al. End-stage renal disease in China. , 1996, Kidney international.